Intuitive Surgical stock steadies after-hours as Barclays lifts target; da Vinci 5 bets build

8 January 2026

New York, Jan 7, 2026, 20:13 ET — After-hours

ISRG shares dipped about 0.1% after the bell, after a choppy regular session
Barclays raised its price target to $686; BTIG lifted its target to $616
Traders look ahead to Intuitive’s conference appearance next week and quarterly results later this month

Intuitive Surgical (ISRG.O) shares eased about 0.1% in after-hours trading on Wednesday to $592.27, after Barclays raised its price target on the robotic-surgery leader to $686 from $635 and kept an “Overweight” rating. The stock traded between $590 and $603.75 during the regular session. TipRanks

The calls land as ISRG flirts with its recent highs and investors keep trying to pin down the next leg of growth: how quickly hospitals upgrade to the company’s newest da Vinci systems, and what that means for recurring sales.

For Intuitive, the hardware sale is only part of the story. The bigger engine is procedure volume — each operation pulls through instruments and accessories, the disposable tools used with the robot, and service revenue tied to the installed base.

BTIG analyst Ryan Zimmerman lifted his price target to $616 from $589 on Wednesday and reiterated a “Buy,” arguing the da Vinci 5 upgrade cycle should add to growth even if it does not rewrite the model overnight. He estimated the new platform could make up about 25.3% of revenue growth in fiscal 2026 and 34.5% in fiscal 2027, and called procedure growth “the key toggle in the entire ISRG model.” Investing

Price targets are brokers’ estimates of where a stock could trade over time; they can move on valuation shifts as much as on fresh fundamentals. Barclays cited a higher target multiple in line with comparable stocks.

The stock has been active this week. ISRG jumped 4.67% on Tuesday to close at $592.85, outpacing medtech peers as Medtronic rose 3.03% and Stryker climbed 5.05%, with ISRG’s volume running above its 50-day average, MarketWatch data showed. MarketWatch

But the setup cuts both ways. With the shares priced for steady procedure growth and a smooth upgrade cycle, any hint of slower hospital demand, tougher competitive pressure, or cost creep could hit sentiment fast.

Next up: investors will watch Intuitive’s slot at the J.P. Morgan Healthcare Conference in San Francisco on Jan. 14, and then the company’s next earnings report, expected on Jan. 22. Jpmorgan

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Perpetua Resources momentum drives valuation questions; P/B at 6.9x vs peers
January 10, 2026, 7:44 AM EST. Perpetua Resources (TSX:PPTA) has surged on price momentum, prompting a closer look at valuation. The stock trades at CA$41.32 and a P/B (price-to-book) of 6.9x, historically rich relative to the Canadian metals and mining group (average ~3.2x) but below a higher peer mean (~14.6x). The model suggests the market prices in growth while balancing risk from it being loss-making, with net income of CA$44.29m and dependence on the Stibnite Gold project. Investors should compare against risk, upside, and a broad peer set. The current gap to analysts' targets implies some upside remains, but the valuation sits at a crossroad between asset quality and earnings visibility.